OBJECTIVE: To determine the current prevalence of Axis I and Axis II psychiatric disorders in patients with fibromyalgia. METHOD: The study sample includes 103 patients with fibromyalgia and 83 control subjects. Axis I and Axis II disorders were determined by structured clinical interviews. RESULTS: The rate of any Axis I psychiatric disorder (47.6% vs. 15.7%), major depression (14.6% vs. 4.8%), specific phobia (13.6% vs. 4.8%), any Axis II disorder (31.1% vs. 13.3%), obsessive-compulsive (23.3% vs. 3.6%) and avoidant (10.7% vs. 2.4%) personality disorders were significantly more common in the patient group compared to the control group. CONCLUSION: Our results suggest that a considerable proportion of patients with fibromyalgia also present with Axis I and Axis II psychopathologies. Copyright 2010. Published by Elsevier Inc.
OBJECTIVE: To determine the current prevalence of Axis I and Axis II psychiatric disorders in patients with fibromyalgia. METHOD: The study sample includes 103 patients with fibromyalgia and 83 control subjects. Axis I and Axis II disorders were determined by structured clinical interviews. RESULTS: The rate of any Axis I psychiatric disorder (47.6% vs. 15.7%), major depression (14.6% vs. 4.8%), specific phobia (13.6% vs. 4.8%), any Axis II disorder (31.1% vs. 13.3%), obsessive-compulsive (23.3% vs. 3.6%) and avoidant (10.7% vs. 2.4%) personality disorders were significantly more common in the patient group compared to the control group. CONCLUSION: Our results suggest that a considerable proportion of patients with fibromyalgia also present with Axis I and Axis II psychopathologies. Copyright 2010. Published by Elsevier Inc.
Authors: Stefan Kempke; Filip Van Den Eede; Chris Schotte; Stephan Claes; Peter Van Wambeke; Boudewijn Van Houdenhove; Patrick Luyten Journal: Int J Behav Med Date: 2013-06
Authors: Martin Offenbaecher; Niko Kohls; Thomas Ewert; Claudia Sigl; Robin Hieblinger; Loren L Toussaint; Fuschia Sirois; Jameson Hirsch; Miguel A Vallejo; Sybille Kramer; Javier Rivera; Gerold Stucki; Jörg Schelling; Andreas Winkelmann Journal: Rheumatol Int Date: 2021-03-05 Impact factor: 2.631
Authors: Laura Gumà-Uriel; M Teresa Peñarrubia-María; Marta Cerdà-Lafont; Oriol Cunillera-Puertolas; Jesús Almeda-Ortega; Rita Fernández-Vergel; Javier García-Campayo; Juan V Luciano Journal: BMC Fam Pract Date: 2016-06-01 Impact factor: 2.497